Veteran NBC News anchor Tom Brokaw continues to manage his long-term health in his mid-80s following a 2013 diagnosis of multiple myeloma, an incurable but treatable blood cancer. His modern health outlook centers on disease maintenance, managing chronic bone damage from earlier spinal fractures, and adjusting to living with chronic illness in advanced age.
Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Readers seeking guidance on multiple myeloma diagnosis, treatment, or management should consult a qualified healthcare professional.
Background and History of Tom Brokaw’s Health Journey
Tom Brokaw, one of American television’s most recognized news anchors and the author of The Greatest Generation, faced a life-altering medical diagnosis in August 2013. While working on a television documentary at the Mayo Clinic in Rochester, Minnesota, Brokaw experienced persistent, severe back pain that led doctors to conduct comprehensive blood work and bone scans. The evaluation revealed that Brokaw had multiple myeloma, a rare form of blood cancer originating in plasma cells within the bone marrow.
Brokaw kept the diagnosis private for several months while initiating intensive treatment before making a public announcement in February 2014. At the time of his public statement, he expressed gratitude to his medical team, family, and colleagues, emphasizing that he planned to continue working while undergoing chemotherapy and maintenance therapies.
In December 2014, Brokaw shared encouraging news with the public: his treatment regimen had successfully driven the cancer into remission. Over the subsequent decade, Brokaw underwent continuous medical surveillance and periodic maintenance therapies. While multiple myeloma remains technically incurable, advancements in targeted oncology treatments have transformed it from a rapidly terminal illness into a manageable chronic condition for many patients.
Brokaw officially retired from NBC News in January 2021 after a distinguished 55-year career at the network, allowing him to shift his focus toward personal health, family life, and writing. In public interviews in recent years, including a candid conversation with former colleague Jane Pauley on CBS Sunday Morning in mid-2023, Brokaw offered rare insight into the physical and emotional reality of growing older with a chronic hematologic malignancy.
Understanding Multiple Myeloma: The Medical Condition
To understand Brokaw’s health trajectory, it is necessary to examine the underlying pathology of multiple myeloma and how it affects the human body over time.
Pathology and Cellular Mechanisms
Multiple myeloma begins when normal plasma cells—white blood cells responsible for producing antibodies to fight infections—undergo cancerous mutations. These abnormal plasma cells multiply uncontrollably within the bone marrow, crowding out healthy red blood cells, white blood cells, and platelets.
As malignant plasma cells proliferate, they produce abnormal antibodies known as monoclonal proteins (M-proteins) or paraproteins. These proteins serve no functional immune purpose and accumulate in the bloodstream and urine, often interfering with kidney function and damaging other internal organs.
- Healthy Bone Marrow
- Healthy Plasma Cells
- Red Blood Cells
- White Blood Cells
- Functional Antibodies
- Myeloma-Affected Marrow
- Malignant Myeloma Cells (Overproduction)
- Low Red Blood Cells (Anemia)
- Low Normal Antibodies (Infection Risk)
- M-Proteins / Paraprotein (Kidney Stress)
Physical Manifestations and Complications
The clinical presentation of multiple myeloma is often summarized by medical specialists using the acronym CRAB:
- Hypercalcemia: Excess calcium in the blood caused by bone tissue breakdown, leading to thirst, nausea, confusion, and muscle weakness.
- Renal Insufficiency: Kidney damage resulting from elevated M-protein levels and hypercalcemia filtering through the renal tubules.
- Anemia: Shortage of red blood cells due to crowded bone marrow, causing persistent fatigue, shortness of breath, and physical weakness.
- Bone Lesions: Lytic bone damage caused by overactive osteoclasts (cells that break down bone) and suppressed osteoblasts (cells that rebuild bone).
For Brokaw, bone damage proved to be one of the most debilitating physical aspects of the condition. Multiple myeloma weakened his spinal vertebrae, resulting in compression fractures that caused significant height loss and severe chronic back pain. Brokaw has noted in interviews that the disease caused him to shrink by approximately two inches, requiring extensive physical therapy and structural medical interventions to stabilize his spine and manage ongoing pain.
Key Milestones in Tom Brokaw’s Health Timeline
The table below outlines the primary events, medical milestones, and public updates regarding Tom Brokaw’s health journey from his initial diagnosis to the current period.
| Year | Milestone / Event | Medical & Life Context |
|---|---|---|
| August 2013 | Initial Diagnosis | Diagnosed with multiple myeloma at the Mayo Clinic after evaluation for severe back pain. |
| February 2014 | Public Announcement | Discloses diagnosis publicly; begins combination chemotherapy while continuing partial work commitments. |
| December 2014 | Entry into Remission | Medical evaluations confirm full clinical remission following initial treatment protocols. |
| April 2015 | Publication of Memoir | Releases A Lucky Life Interrupted, detailing his initial battle, treatment side effects, and emotional adjustments. |
| January 2021 | Retirement from NBC News | Concludes 55-year broadcast journalism career to prioritize health management and time with family. |
| June 2023 | CBS Sunday Morning Interview | Discusses physical toll of myeloma, spinal damage, loss of height, and managing chronic cancer in his 80s. |
| 2024–2026 | Ongoing Maintenance & Stability | Manages long-term remission with continuous maintenance therapy and age-appropriate physical care. |
Modern Management of Multiple Myeloma in Senior Patients
The management of multiple myeloma in patients who are in their 80s involves balancing effective cancer control with preserving functional independence and quality of life. Medical strategies have advanced substantially since Brokaw was first diagnosed in 2013.
Initial and Maintenance Pharmacotherapy
Traditional treatment for eligible, younger patients often involves high-dose chemotherapy followed by an autologous stem cell transplant (ASCT). However, for older adults or individuals with co-existing health conditions, low-intensity continuous maintenance protocols are typically preferred to avoid severe toxicity.
According to clinical research synthesized by the National Cancer Institute, modern myeloma care relies heavily on three core drug classes:
- Immunomodulatory Drugs (IMiDs): Medications such as lenalidomide (Revlimid) and pomalidomide enhance the immune system’s ability to recognize and destroy myeloma cells while inhibiting tumor blood supply.
- Proteasome Inhibitors (PIs): Agents like bortezomib (Velcade) and carfilzomib target the protein disposal system inside cancer cells, causing toxic protein buildup that triggers cell death.
- Monoclonal Antibodies: Targeted biologic therapies, such as daratumumab (Darzalex), bind directly to specific markers (like CD38) on myeloma cells, marking them for destruction by the patient's immune system.
Brokaw’s long-term survival and disease control reflect the success of modern immunomodulatory maintenance therapies, which allow patients to maintain low or undetectable levels of disease over extended periods without the severe systemic impact of traditional high-dose chemotherapy.
Bone Health Stabilization
Because myeloma causes active destruction of bone matrix tissue, bone-directed supportive therapies are a critical component of care.
- Bisphosphonates: Drugs such as zoledronic acid or pamidronate help inhibit osteoclast activity, reducing the risk of bone fractures and controlling hypercalcemia.
- RANK Ligand Inhibitors: Targeted therapies like denosumab provide an alternative option for strengthening bone density, particularly for patients with compromised kidney function.
- Surgical and Structural Interventions: Procedures such as vertebroplasty or kyphoplasty—wherein medical cement is injected into fractured vertebrae—are often utilized to restore spinal stability and alleviate localized back pain.
Quality-of-Life Considerations for Octogenarians
For individuals managing chronic myeloma into their 80s, treatment regimens are carefully adjusted to prioritize daily function, renal safety, and energy conservation. Physicians monitor blood counts, serum free light chains, and kidney function parameters regularly to catch early signs of relapse while avoiding unnecessary drug side effects.
Public Advocacy and Contributions to Cancer Literacy
Beyond his journalistic achievements, Brokaw’s public handling of his diagnosis has contributed significantly to general understanding of blood cancers and patient advocacy.
- TOM BROKAW HEALTH IMPACT
- Patient Literacy: Demystified complex blood cancer care
- Structural Reform: Highlighted patient navigation and care coordination
- Psychological Normalization: Framed cancer as manageable
Demystifying Complex Medical Diagnoses
When Brokaw announced his illness in 2014, multiple myeloma was far less understood by the general public than cancers such as breast, lung, or prostate cancer. By speaking openly about bone marrow biopsies, blood protein levels, and maintenance medications, Brokaw brought broad attention to hematologic malignancies.
His 2015 book, A Lucky Life Interrupted: A Memoir of Hope, chronicled his personal journey through diagnosis, treatment side effects, and recovery. In the memoir, he described the psychological adjustment required when transitioning from an active public figure to a patient navigating complex medical protocols.
Highlighting Healthcare Coordination and Patient Self-Advocacy
Brokaw has frequently emphasized the importance of integrated care teams and patient self-advocacy. In public addresses and written works, he highlighted several key recommendations for patients facing serious health diagnoses:
- Seeking Specialized Care: Encouraging patients to consult hematologist-oncologists who specialize specifically in plasma cell disorders at major academic cancer centers.
- Organizing Support Systems: Relying on family, close caregivers, and professional coordinators to track complex medication schedules and appointments.
- Maintaining Open Communication: Communicating transparently with treating physicians regarding side effects, fatigue levels, and pain to enable timely treatment adjustments.
Current Status and Brokaw's Outlook
As of the current 2025–2026 period, Tom Brokaw remains in stable health while living quietly with his family, spending time between New York and his ranch in Montana. At age 86, his health outlook is defined by management rather than cure—a reality common to long-term multiple myeloma survivors.
Brokaw’s public statements reflect a practical, reflective perspective on aging and chronic illness. While acknowledging the physical limitations imposed by spinal changes and ongoing maintenance treatments, he has continued to focus on personal writing, family engagements, and periodic commentary on American public life.
His case illustrates the significant progress achieved in hematology over the past two decades. Where a multiple myeloma diagnosis historically carried a limited median survival expectation of three to five years, modern targeted regimens, immunotherapies, and comprehensive bone support enable many senior patients to achieve extended periods of disease stability while maintaining meaningful daily routines.
Frequently Asked Questions
What condition was Tom Brokaw diagnosed with?
Tom Brokaw was diagnosed with multiple myeloma in August 2013. Multiple myeloma is a form of cancer that originates in plasma cells inside the bone marrow, affecting blood cell production, bone health, and kidney function.
Is Tom Brokaw currently in remission from multiple myeloma?
Tom Brokaw achieved clinical remission in December 2014 following intensive chemotherapy and targeted biological therapies. Because multiple myeloma is generally considered incurable, he continues long-term disease management and routine monitoring to ensure ongoing stability.
How has multiple myeloma affected Tom Brokaw physically?
The primary physical impact Brokaw experienced was bone loss and spinal damage. The cancer caused vertebrae compression fractures, resulting in a loss of about two inches of height and chronic back pain that required physical therapy and pain management strategies.
What is the typical life expectancy for someone with multiple myeloma?
Survival rates for multiple myeloma have improved substantially due to newer therapies like immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies. According to clinical data from the Mayo Clinic, many patients live five to ten years or longer after diagnosis, depending on age, overall health, and genetic sub-types of the disease.
Is Tom Brokaw still working in broadcast journalism?
Tom Brokaw retired from NBC News in January 2021 after 55 years with the network. While he no longer works as a daily broadcaster, he occasionally participates in interviews and continues writing.
Summary and Key Takeaways
Tom Brokaw’s ongoing management of multiple myeloma highlights the advancements in modern blood cancer treatment, which allow senior patients to control complex malignancies as chronic conditions. For patients, families, and individuals following health developments in hematology, key insights from Brokaw’s experience include:
- Early Diagnosis and Specialist Care: Prompt evaluation of unexplained bone pain or persistent fatigue can lead to earlier detection of plasma cell disorders. Consulting specialized oncology teams improves access to targeted therapies.
- Multimodal Treatment Approaches: Combining targeted immunomodulatory medications with bone-strengthening agents helps control disease progression while preserving skeletal integrity.
- Focus on Functional Quality of Life: Patient management in advanced age prioritizes balancing therapeutic efficacy with side-effect management, functional mobility, and mental well-being.
